BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

First Closing and Launch of BioDiscovery, Inc. 4


7/10/2012 9:31:05 AM

July 10 2012 -- Edmond de Rothschild Investment Partners is pleased to announce the first closing and launch of the fourth fund in its BioDiscovery franchise dedicated to investing in Life Sciences in France and in Europe.

Thanks to the renewed confidence of its existing institutional investor base as well as new investors who decided to participate in this new fund Edmond de Rothschild Investment Partners reached its objective of €125 million for the first closing in the expected timeframe and confirms its final objective of about €200 million by the end of the year.

Edmond de Rothschild Investment Partners will deploy the same strategy for BioDiscovery 4 as for its previous funds. The team will lead investments in 15 to 20 life science companies across all stages of development. The investments will be made both in therapeutic drug development companies and a combination of medical technology and molecular diagnostic companies. The fund will invest mainly in Europe.

About Edmond de Rothschild Investment Partners

Paris-based Edmond de Rothschild Investment Partners is dedicated to minority investments into privately-owned companies. It has currently €1 billion under management which is being invested primarily in Life Sciences Venture Capital and Growth Capital.

Its Life Sciences team of eight professionals brings together over 50 years of experience in the Life Science industry and more than 100 years of private equity and venture capital experience. The team now has €355 million under management through its BioDiscovery funds.

Edmond de Rothschild Investment Partners is an independently managed affiliate of Edmond de Rothschild Group. For more information please visit: www.edrip.fr.

About Edmond de Rothschild Group

Edmond de Rothschild Group is an independent, family-owned group focused on private banking and asset management. Founded in 1953, Edmond de Rothschild Group has been chaired since 1997 by the founder's son, Baron Benjamin de Rothschild. The Group has more than $150 billion in assets under management and 2,700 employees in 30 offices around the world. In addition to its main activities in asset management and private banking, the Group’s financial activities include fund administration and corporate advisory services.

Disclaimer

This document is for information only. Any investment in private equity through capital development or venture capital funds involves specific risks like capital loss risk, discretionary management risk and liquidity risk. All potential investors should liaise with their service provider or advisor to make their own opinion on the inherent risks to each investment independently of Edmond de Rothschild Investment Partners and on such investment suitability with their needs and personal circumstances.

EDMOND DE ROTHSCHILD INVESTMENT PARTNERS 47, rue du Faubourg Saint-Honoré -75401 Paris Cedex 08 A simplified joint-stock company registered under French law with a capital of EUR 501,500 - 444 071 989 R.C.S. Paris.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES